Marker Therapeutics reports non-clinical data showing MT-401 + HMA synergy; awarded $2M NIH grant

Marker Therapeutics, Inc.

Non-clinical in vitro data: MT-401 after HMA (5'-Azacytidine) significantly decreased AML THP-1 cell growth vs. either agent alone, suggesting synergy.
NIH SBIR grant of $2 million will fund a nationwide multi-center Phase 2b trial of MT-401 with HMA pre-treatment in AML patients post-HSCT.
MT-401 targets four antigens (Survivin, PRAME, WT-1, NY-ESO-1); HMA upregulated Survivin expression in AML cells.
Company plans to incorporate findings into current AML clinical study; revised design details expected in Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.